| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -334,259 | -226,219 |
| Depreciation and amortization expense | - | 1,005 |
| Stock-based compensation expense | 34,625 | 23,543 |
| Depreciation and amortization expense | 1,528 | 1,000 |
| Non-cash lease expense | 128 | 32 |
| Non-cash interest expense | 62 | 2 |
| Accretion of premium on marketable securities | -1,447 | -1,079 |
| Loss (gain) on sale of marketable securities | -14 | -14 |
| Loss (gain) on disposal of property and equipment | -95 | -95 |
| Prepaid expenses and other current assets | -3,184 | -2,795 |
| Other non-current assets | 12,991 | - |
| Accounts payable and other liabilities | 17,714 | -756 |
| Net cash used in operating activities | -291,375 | -200,596 |
| Purchases of property and equipment | 1,436 | 1,041 |
| Advance payment for long-lead equipment | 18,790 | - |
| Purchases of marketable securities | 153,823 | 106,903 |
| Maturities of marketable securities | 135,847 | 107,708 |
| Sales of marketable securities | 8,469 | 8,468 |
| Net cash used in investing activities | -29,733 | 8,232 |
| Proceeds from issuance of common stock in public offering, net of issuance costs | 215,803 | 0 |
| Proceeds from issuance of common stock in at-the-market offering, net of issuance costs | 140,653 | 140,653 |
| Proceeds from exercise of stock options | 4,633 | 2,560 |
| Proceeds from issuance of long-term debt, net of issuance costs paid | 98,802 | 98,802 |
| Payment of debt issuance costs | 549 | - |
| Net cash provided by financing activities | 459,342 | 242,015 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 138,234 | 49,651 |
| Cash and cash equivalents at beginning of period | 437,391 | - |
| Cash and cash equivalents at end of period | 575,625 | - |
Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. (DYN)